3702-09-8

Usage

Uses

Used in Pharmaceutical Research and Development:
2-cyclopentylpyrazol-3-amine is used as a key building block for the synthesis of novel drugs, particularly in the development of pharmaceuticals targeting various diseases and conditions. Its unique structure and reactivity make it a valuable component in the creation of new therapeutic agents.
Used in Academic Research:
2-cyclopentylpyrazol-3-amine is utilized in academic research to study its unique properties and reactivity. Researchers explore its potential applications and investigate its interactions with other compounds, aiming to gain a deeper understanding of its capabilities and limitations.
Used in Chemical Testing:
2-cyclopentylpyrazol-3-amine is employed in chemical testing to evaluate its properties and reactivity. This helps in determining its suitability for various applications and in identifying potential improvements or modifications that can enhance its performance.
Used in Cancer Treatment:
2-cyclopentylpyrazol-3-amine is being studied for its potential applications in the treatment of cancer. Its unique structure and reactivity may offer new avenues for developing therapeutic agents that can target and combat cancer cells effectively.
Used in Inflammation Management:
2-cyclopentylpyrazol-3-amine is also being investigated for its potential use in managing inflammation. Its unique properties may contribute to the development of new anti-inflammatory drugs, providing effective treatment options for various inflammatory conditions.

InChI:InChI=1/C8H13N3/c9-8-5-6-10-11(8)7-3-1-2-4-7/h5-7H,1-4,9H2

Upstream product

• 71-36-3 butan-1-ol 
• 21253-97-4 ethyl 5-amino-1-cyclopentyl-1H-pyrazole-4-carboxylate 
• 30923-92-3 cyclopentylhydrazine 
• 6162-76-1 cyanoacetaldehyde 

Relevant academic research and scientific papers

The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition

In this study, a series of sulfonamide compounds was designed and synthesized through the systematic optimization of the antibacterial agent sulfaphenazole for the treatment of Mycobacterium tuberculosis (M. tuberculosis). Preliminary results indicate that the 4-aminobenzenesulfonamide moiety plays a key role in maintaining antimycobacterial activity. Compounds 10c, 10d, 10f and 10i through the optimization on phenyl ring at the R2 site on the pyrazole displayed promising antimycobacterial activity paired with low cytotoxicity. In particular, compound 10d displayed good activity (MIC = 5.69 μg/mL) with low inhibition of CYP 2C9 (IC50 > 10 μM), consequently low potential risk of drug-drug interaction. These promising results provide new insight into the combination regimen using sulfonamide as one component for the treatment of M. tuberculosis.

The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist

The identification of novel, potent, non-steroidal/small molecule functional GR antagonist GSK1564023A selective over PR is described. Associated structure-activity relationships and the process of optimisation of an initial HTS hit are also described.

Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines

A method for inhibiting neoplastic cells and related conditions by exposing them to substituted N-cycloalkylmethyl-1H-pyrazolo?3,4-b!quinolin-4-amines.

Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof

Substituted N-cycloalkylmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines, pharmaceutical compositions containing them and methods for a) effecting c-GMP-phosphodiesterase inhibition, b) treating heart failure and/or hypertension, c) reversing or reducing nitrate-induced tolerance and d) treating angina pectoris, congestive heart disease and myocardial infarction utilizing them.